Immunologics and chemotherapeutics for renal cell carcinoma

Seminars in Interventional Radiology

Volumn 31, Issue 1, 2014, Pages 91-97

  Diamond, Elan ^a   Riches, Jamie ^b   Faltas, Bishoy ^a   Tagawa, Scott T ^a   Nanus, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

chemotherapy; interleukin 2; interventional radiology; mTOR inhibitors; renal cell carcinoma; VGEF inhibitors

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UBIQUITINATION;

EID: 84896726559     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0033-1363848     Document Type: Article

References (68)

1. Chin A. I., Lam J. S., Figlin R. A., Belldegrun A. S. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol: 2006; 8 1 1 7
2. SEER Cancer Statistics Review, 1975-2010. In: Howlader N., Noone A., Krapcho M., et al, eds. Bethesda, MD National Cancer Institute: 2013;. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed June 12, 2013
3. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer: 1993; 71 (3, Suppl) 1098 1109
4. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev: 2005; 1 CD001425
5. Pyrhönen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol: 1999; 17 9 2859 2867
6. Fyfe G., Fisher R. I., Rosenberg S. A., Sznol M., Parkinson D. R., Louie A. C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol: 1995; 13 3 688 696
7. Fisher R. I., Rosenberg S. A., Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am: 2000; 6 01 S55 S57
8. McDermott D. F., Ghebremichael M. S., Signoretti S., et al. The high-dose aldesleukin (HD IL-2) SELECT trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol ASCO Annual Meeting Abstracts: 2010; 28 (15, Suppl): 4514
9. McDermott D. F. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res: 2007; 13 2 Pt 2 716s 720s
10. Arjumand W., Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol: 2012; 33 1 9 16
11. Kim W. Y., Kaelin W. G. Role of VHL gene mutation in human cancer. J Clin Oncol: 2004; 22 24 4991 5004
12. Tory K., Brauch H., Linehan M., et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst: 1989; 81 14 1097 1101
13. Yang J. C., Haworth L., Sherry R. M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med: 2003; 349 5 427 434
14. Escudier B., Bellmunt J., Négrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol: 2010; 28 13 2144 2150
15. Rini B. I., Halabi S., Rosenberg J. E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol: 2010; 28 13 2137 2143
16. Escudier B., Eisen T., Stadler W. M., et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol: 2009; 27 20 3312 3318
17. Escudier B., Szczylik C., Hutson T. E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol: 2009; 27 8 1280 1289
18. Hutson T. E., Lesovoy V., Al-Shukri S. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol: 2013; 14 13 1287 1294
19. Motzer R. J., Michaelson M. D., Redman B. G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol: 2006; 24 1 16 24
20. Motzer R. J., Rini B. I., Bukowski R. M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA: 2006; 295 21 2516 2524
21. Motzer R. J., Hutson T. E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol: 2009; 27 22 3584 3590
22. Dudek A. Z., Raza A., Chi M., et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer: 2013; 11 2 155 160
23. Motzer R. J., Hutson T. E., Olsen M. R., et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol: 2012; 30 12 1371 1377
24. Hutson T. E., Davis I. D., Machiels J. P., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol: 2010; 28 3 475 480
25. Sternberg C. N., Davis I. D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol: 2010; 28 6 1061 1068
26. Motzer R. J., Hutson T. E., Cella D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med: 2013; 369 8 722 731
27. Rixe O., Bukowski R. M., Michaelson M. D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol: 2007; 8 11 975 984
28. Rini B. I., Wilding G., Hudes G., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol: 2009; 27 27 4462 4468
29. Rini B. I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet: 2011; 378 9807 1931 1939
30. Rini B. I., Melichar B., Ueda T., et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol: 2013; 14 1233 1242
31. Hudes G., Carducci M., Tomczak P., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med: 2007; 356 22 2271 2281
32. Dutcher J. P., de Souza P., McDermott D., et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol: 2009; 26 2 202 209
33. Hutson T. E., Escudier B., Esteban E., et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol: 2013
34. Motzer R. J., Escudier B., Oudard S., et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet: 2008; 372 9637 449 456
35. Kuebler J. P., Hogan T. F., Trump D. L., Bryan G. T. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep: 1984; 68 6 925 926
36. Hrushesky W. J., von Roemeling R., Lanning R. M., Rabatin J. T. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol: 1990; 8 9 1504 1513
37. Desai A. A., Vogelzang N. J., Rini B. I., Ansari R., Krauss S., Stadler W. M. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer: 2002; 95 8 1629 1636
38. George C. M., Vogelzang N. J., Rini B. I., Geoffroy F. J., Kollipara P., Stadler W. M. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol: 2002; 13 1 116 120
39. Bennouna J., Delva R., Gomez F., et al. A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology: 2003; 64 1 25 27
40. Haas N. B., Lin X., Manola J., et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol: 2012; 29 2 761 767
41. Nanus D. M., Garino A., Milowsky M. I., Larkin M., Dutcher J. P. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer: 2004; 101 7 1545 1551
42. Fosså S. D., Raabe N., Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study. Br J Urol: 1989; 64 5 468 471
43. Rizzo M., Bartoletti R., Selli C., Sicignano A., Criscuolo D. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma. Eur Urol: 1989; 16 4 271 277
44. Neidhart J. A., Anderson S. A., Harris J. E., et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol: 1991; 9 5 832 836
45. Pyrhönen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol: 1999; 17 9 2859 2867
46. Ellerhorst J. A., Sella A., Amato R. J., et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer: 1997; 80 11 2128 2132
47. Kirchner G. I., Franzke A., Buer J., et al. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol: 1998; 46 1 5 10
48. Joffe J. K., Banks R. E., Forbes M. A., et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol: 1996; 77 5 638 649
49. Dutcher J. P., Fisher R. I., Weiss G., et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am: 1997; 3 3 157 162
50. Gitlitz B. J., Belldegrun A., Figlin R. A. Immunotherapy and gene therapy. Semin Urol Oncol: 1996; 14 4 237 243
51. Atzpodien J., Kirchner H., Jonas U., et al. Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol: 2004; 22 7 1188 1194
52. Hongyun L., Zhihong C., Xiangqing Y., et al. Phase II study of sorafenib combined with gemcitabine and 5-fluorouracil in patients with metastatic renal cell carcinoma: preliminary results. J Clin Oncol: 2009; 27 (suppl): abstr e16093
53. Tagawa S. T., Milowsky M. I., Jeske S., et al. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. Am J Clin Oncol: 2011; 34 5 443 448
54. Tagawa S. T., Saran A., Akhtar N. H., et al. Final phase II results of NCI 6981: a phase I/II study of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma. J Clin Oncol: 2011; 29 (suppl): abstr e15165
55. Bellmunt J., Trigo J. M., Calvo E., et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol: 2010; 11 4 350 357
56. Pandya S. S., Mier J. W., McDermott D. F., Cho D. C. Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int: 2011; 108 8 Pt 2 E245 E249
57. Michaelson M. D., Zhu A. X., Ryan D. P., et al. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer: 2013; 108 7 1393 1401
58. Suarez C., Gallardo E., Rodon Ahnert J., et al. Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. ASCO Meeting Abstracts: 2011; 29 e15095
59. Jonasch E., Lal L. S., Atkinson B. J., et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int: 2011; 107 5 741 747
60. Staehler M., Haseke N., Roosen A., et al. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res: 2010; 15 287 291
61. Michaelson M. D., McDermott D. F., Atkins M. B., et al. Combination of antiangiogenic therapy and cytotoxic chemotherapy for sarcomatoid renal cell carcinoma. J Clin Oncol: 2013; 31 (suppl):abstr 4512
62. Jonasch E., Lal L. S., Atkinson B. J., et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int: 2011; 107 5 741 747
63. Chung E. K., Posadas E. M., Kasza K., et al. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol: 2011; 34 2 150 154
64. Thompson R. H., Gillett M. D., Cheville J. C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A: 2004; 101 49 17174 17179
65. Cho D. C., Sosman J. A., Sznol M., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol: 2013; 31 (suppl):abstr 4505
66. Drake C. G., McDermott D. F., Sznol M., et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. J Clin Oncol: 2013; 31 (suppl):abstr 4514
67. Amin A., Ernstoff M. S., Infante J. R., et al. A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol: 2013; 31 (suppl):abstr TPS4593
68. Liu W., Shen S. M., Zhao X. Y., Chen G. Q. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol: 2012; 3 2 165 178